Gain Therapeutics, Inc. (NASDAQ:GANX) Given Average Rating of “Moderate Buy” by Brokerages

Gain Therapeutics, Inc. (NASDAQ:GANX) has earned an average recommendation of “Moderate Buy” from the eight ratings firms that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. The average 12-month price target among analysts that have covered the stock in the last year is $7.8571.

A number of equities analysts recently weighed in on the stock. Roth Capital lowered their target price on shares of Gain Therapeutics from $7.00 to $6.00 and set a “buy” rating on the stock in a report on Wednesday, August 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Gain Therapeutics in a report on Thursday. BTIG Research restated a “buy” rating and set a $9.00 target price on shares of Gain Therapeutics in a research note on Wednesday, October 15th. HC Wainwright reaffirmed a “buy” rating and set a $8.00 target price on shares of Gain Therapeutics in a report on Monday, December 1st. Finally, Maxim Group increased their price target on shares of Gain Therapeutics from $5.00 to $7.00 and gave the company a “buy” rating in a report on Tuesday, October 7th.

Institutional Trading of Gain Therapeutics

Several hedge funds have recently added to or reduced their stakes in the company. Wealth Enhancement Advisory Services LLC bought a new stake in Gain Therapeutics in the 3rd quarter valued at $28,000. JPMorgan Chase & Co. acquired a new stake in shares of Gain Therapeutics during the third quarter worth $47,000. Benedict Financial Advisors Inc. lifted its holdings in shares of Gain Therapeutics by 55.6% during the third quarter. Benedict Financial Advisors Inc. now owns 35,000 shares of the company’s stock worth $62,000 after buying an additional 12,500 shares in the last quarter. Squarepoint Ops LLC bought a new stake in shares of Gain Therapeutics in the third quarter valued at about $68,000. Finally, Kovitz Investment Group Partners LLC acquired a new position in shares of Gain Therapeutics in the first quarter valued at about $91,000. 11.97% of the stock is owned by institutional investors and hedge funds.

Gain Therapeutics Stock Performance

GANX opened at $3.85 on Monday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 2.52 and a current ratio of 2.52. The business’s 50-day simple moving average is $2.36 and its 200 day simple moving average is $1.95. The firm has a market capitalization of $148.07 million, a PE ratio of -6.31 and a beta of 0.05. Gain Therapeutics has a 52-week low of $1.41 and a 52-week high of $3.98.

Gain Therapeutics (NASDAQ:GANX) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.15) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.15). As a group, sell-side analysts expect that Gain Therapeutics will post -1 earnings per share for the current fiscal year.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.